Peptide mimicry of adenocarcinoma-associated carbohydrate antigens

Hybridoma

Volumn 16, Issue 1, 1997, Pages 3-10

  Kieber Emmons, Thomas ^a   Luo, Ping ^a   Qiu, Jianping ^a   Agadjanyan, Michael ^a   Carey, Lisa ^a   Hutchins, Wendy ^b   Julie Westerink, M A ^b   Steplewski, Zenon ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE ANTIGEN; PEPTIDE;

BREAST CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; CONFERENCE PAPER; CROSS REACTION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MOLECULAR MIMICRY; PRIORITY JOURNAL;

EID: 0030930945     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1997.16.3     Document Type: Conference Paper

References (23)

1. Hakomori S: Possible functions of tumor-associated carbohydrate antigens. Curr Opin Immunol 1991;3:646-653.
2. Hakomori S: Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 1989;52:257-331.
3. Dennis JW, and Laferte S: Oncodevelopmental expression of GlcNAcβ1,6Manαl, 6 Manαl-branched asparagine-linked oligosaccharides in murine tissues and human breast carcinoma. Cancer Res 1989;49:945-950.
4. Hiraizumi S, Takasaki S, Ochuchi N, Harada Y., Nose M., Mon S, and Kobata A: Altered glycosylation of membrane glycoproteins associated with human mammary carcinoma. Jpn J Cancer Res 1992;83:1063-1072.
5. MacLean GD, Reddish M, Koganty RR, Wong T, Gandhi S, Smolenski M, Samuel J, Nabholtz JM, and Longenecker BM: Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 1993;36:215-222.
6. Springer GF, Desai PR, Tegtmeyer H, Carlstedt SC, and Scanlon EF: T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced human breast carcinoma. Cancer Biother 1994;9:7-15.
7. Toyokuni T, Hakomori S, and Singhal AK: Synthetic carbohydrate vaccines: synthesis and immunogenicity of Tn antigen conjugates. Bioorg Medic Chem 1994;2:1119-1132.
8. Adluri S, Helling F, Ogata S, Zhang S, Itzkowitz SH, Lloyd KO, and Livingston PO: Immunogenicity of synthetic TF-KLH (key-hole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol Immunother 1995;41:185-192.
9. Bremer EG, Levery SB, Sonnino S, Ghidoni R, Canevari S, Kannagi R, and Hakomori S: Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBR1 expressed in normal and neoplastic epithelial cells of human mammary gland. J Biol Chem 1984;259:14773-14777.
10. Nakagoe T, Fukushima K, Hirota M, Kusano H, Kawahara K, Ayabe H, Tomita M, and Kamihira S. Immunohistochemical expression of blood group substances and related carbohydrate antigens in breast carcinoma. Jpn J Cancer Res 1991;82:559-568.
11. Blaszczyk-Thurin M, Thurin J, Hindsgaul O, Karlsson KA, Steplewski Z, and Koprowski H: Y and blood group B type 2 glycolipid antigens accumulate in a human gastric carcinoma cell line as detected by monoclonal antibody. Isolation and characterization by mass spectrometry and NMR spectroscopy. J Biol Chem 1987;262:372-379.
12. Rodeck U, Herlyn M, Leander K, Borlinghaus P, and Koprowski H: A mucin containing the X, Y, and H type 2 carbohydrate determinants is shed by carcinoma cells. Hybridoma 1987;6:389-401.
13. Miyake M, Taki T, Hitomi S, and Hakomori S: The correlation of expression of H/Ley/Leb antigens with survival of patients with carcinoma of the lung. Biochemistry 1992;327:14-18.
14. Ma XC, Terata N, Kodama M, Jancic S, Hosokawa Y, and Hattori T: Expression of sialyl-Tn antigen is correlated with survival time of patients with gastric carcinomas [see comments]. Eur J Cancer 1993;29A:1820-1823.
15. Comments 1994;30A:1398-1399 .
16. Ravindranath MH, and Morton DL: Role of gangliosides in acitve immunotherapy with melanoma vaccine. [Review]. Int Rev Immunol 1991;7:303-29.
17. Mond JJ, Lees A, and Snapper CM: T cell-independent antigens type 2. [Review], Annu Rev Immunol 1995;13:655-692.
18. Helling F, Shang A, Calves M, Zhang S, Ren S, Yu RK, Oettgen HF, and Livingston PO: GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res 1994;54:197-203.
19. Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Yao TJ, Oettgen HF, and Livingston PO: GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995;55:2783-2788.
20. Livingston PO: Construction of cancer vaccines with carbohydrate and protein (peptide) tumor antigens. [Review]. Curr Opin Immunol 1992;4:624-629.
21. Livingston PO, Calves MJ, Helling F, Zollinger WD, Blake MS, and Lowell GH: GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3. Vaccine 1993;11:1199-1204.
22. Livingston PO, Adluri S, Helling F, Yao TJ, Kensil CR, Newman MJ, and Marciani D: Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 1994;12:1275-1280.
23. Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, and Ritter G: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-1044.